Second-line therapy in extensive-stage small cell lung cancer: an unmet need highlighted by real-world evidence from the LALUCA registry.
BACKGROUND Extensive-stage small cell lung cancer (ES-SCLC) has a dismal prognosis as patients progress within months after first-line systemic treatment. Until recently, topotecan was the only approved second-line treatment in Europe. However, due to its limited efficacy, various treatment strategies are being employe...